Jiangsu Hengrui Medicine Co Ltd - Company Profile
Powered by 
All the data and insights you need on Jiangsu Hengrui Medicine Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Jiangsu Hengrui Medicine Co Ltd Strategy Report
- Understand Jiangsu Hengrui Medicine Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
Headquarters
China
Address
No.7 Kunlunshan Road, Lianyungang Eco & Tech Development Zone, Jiangsu, 222000
Website
www.hengrui.com
Telephone
86 518 81220983
No of Employees
20,636
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600276 (SHA)
Revenue (2022)
$3.2B
-17.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-13.8%
(2022 vs 2021)
Market Cap*
$42.5B
Net Profit Margin (2022)
XYZ
5.0%
(2022 vs 2021)
* As of and is in US$
Jiangsu Hengrui Medicine Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Antitumor Drugs: | Interventional Imaging Solutions | Callispheres |
| Apatini Tablets | Supply and Distribution | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into partnership with Aiolos Bio, Inc. for global development and commercialization of the drug outside of greater China. |
| 2023 | Regulatory Approval | In January, the company's Camrelizumab (Erica) Combined with Apatinib (Aitan) received US FDA approval for tretament of Advanced Liver Cancer. |
| 2022 | Regulatory Approval | In July, the company and its subsidiaries Shanghai Shengdi Pharmaceutical Co Ltd and Suzhou Shengdia Biopharmaceutical Co Ltd obtained the drug clinical trial approval notice approved and issued by the State Drug Administration and approved the development of a SHR-A1811 for injection. |
Competitor Comparison
| Key Parameters | Jiangsu Hengrui Medicine Co Ltd | Sinopharm Group Co Ltd | Sino Biopharmaceutical Ltd | Chongqing Laimei Pharmaceutical Co Ltd | Akeso Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Lianyungang | Shanghai | Hong Kong | Chongqing | Zhongshan |
| State/Province | Jiangsu | Shanghai | - | Chongqing | Guangdong |
| No. of Employees | 20,636 | 113,362 | 26,079 | 905 | 2,520 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sun Piaoyang | Chairman | Executive Board | 2020 | 64 |
| Sun Jieping | Deputy General Manager; Director | Executive Board | - | 52 |
| Lianshan Zhang | Director; Deputy General Manager | Executive Board | 2012 | 62 |
| Dai Hongbin | Director; Deputy General Manager | Executive Board | - | 46 |
| Wang Quanre | Deputy General Manager | Senior Management | - | 36 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward